This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ProfNet Experts Available On Pharmaceutical Patents, FBI Email Access, Energy Investments

NEW YORK, April 10, 2013 /PRNewswire/ -- Below are experts from the ProfNet network that are available to discuss timely issues in your coverage area. If you are interested in interviewing any of the experts, please contact them via the contact information at the end of the listing. To receive updates by email, drop us a note at with the industries you cover, and we'll add you to the appropriate edition.

If you are in need of additional experts, you can also submit a query to the hundreds of thousands of experts in our network. You can filter your request by institution type and geographic location to get the most targeted responses. The best part? It's free! Just fill out the query form to get started.

If you have any questions or need assistance with any aspect of ProfNet, please drop us a note at

  • Top Indian Court Rejects Novartis Patent
  • Concern Over FBI's Real-Time Access to Emails
  • Lessons from Amway's Hard-Won Success in China
  • Investments in Energy
  • Responsive Web Design: Future of Internet

  • Food/Health Writer – (CA)
  • Sports Producer – NBC Sports (CT)
  • Copy Editor – Augusta Chronicle (GA)

  • How to Become a Freelancer and Ghostwriter
  • Social Media in the Newsroom
  • Where Did Your Experts Pop Up in March?

****************EXPERT ALERTS:Top Indian Court Rejects Novartis PatentDr. Philip AlcabesProfessor, School of Nursing; Director, Public Health Program Adelphi University, Garden City, N.Y."The decision in the Indian courts challenges the capacity of wealthy pharmaceutical companies to deny to poor people medicines needed to relieve suffering or prolong life. In that sense, it's an advance in the pursuit of human rights. But it's also complicated, and invites a host of further questions about access to medicine and human rights. In the case in question, the Swiss drug maker Novartis, one of the wealthiest companies in the world, lost in its attempt to prevent Indian drug companies from selling the drug Glivec, on which Novartis was trying to hold a monopoly. Glivec (also Gleevec) is essentially the only treatment for patients with chronic myeloid leukemia. It can make the difference between rapid death and a few years of life. The court ruling doesn't change the fundamental inequities in access to medicines worldwide.  It doesn't directly improve the life of any individual cancer patient. It doesn't affect lack of health care in wealthy countries like ours. And the main beneficiaries will be Indian drug companies -- not people who can't afford any medicine at all. But it alters what one Novartis official unabashedly referred to as the 'intellectual property ecosystem' in India. In doing that, it questions the reach of corporations. Now there are new questions to answer in regard to pharmaceuticals and the widely recognized human right to a decent chance in life."Dr. Alcabes is author of "Dread:  How Fear and Fantasy Have Fueled Epidemics from the Black Death to Avian Flu," and has studied the history, ethics, and policy of public health. He is a founding member of the Scientific Advisory Committee of the World Trade Center Health Registry, and has consulted on public health policy and AIDS-prevention projects in Eastern Europe for the Open Society Institute's International Harm Reduction Development Program, World AIDS Foundation, and Fogarty International Foundation of the National Institutes of Health. He is known for his critical eye on public health policy, frequently quoted by news media such as WNYC radio, C-SPAN TV and "The Daily Show." His op-ed pieces have appeared in the Washington Post, The Nation, New Scientist, and other publications. He holds a Ph.D. in infectious-disease epidemiology from the Johns Hopkins School of Hygiene and Public Health.Website: http://chi.adelphi.eduMedia Contact: Kali Chan,

Concern Over FBI's Real-Time Access to Emails Jimmy ArdoinAttorneyArdoin Law PLLC, Houston"The FBI's general counsel says the bureau has made it a top priority this year to gain the power to wiretap, in real time, all forms of Internet conversation, social media and cloud storage. With so much of people's lives now in the 'cloud,' the public should have a great concern about who is accessing their digital information and why. The FBI should tell the millions of law-abiding Americans exactly what it is they want and why they need this real-time access to emails, Facebook accounts and documents. The FBI is likely to succeed in getting most, if not all, of what it wants, but in order to ensure that their requests comport with the Constitution and do not violate the rights of innocent Americans, more transparency on the part of the bureau is a must."Media Contact: Alan Bentrup,

Lessons from Amway's Hard-Won Success in China Tom FoxFCPA and Compliance Ethics Lawyer and Blogger Tom Fox Law in Houston"Door-to-door sales powerhouse Amway entered the Chinese market in 1995, only to have its business model outlawed three years later by a government suspicious of Western direct sales tactics. Amway brilliantly looked to its core values, considered the long term, and developed a new business model by building stores, while simultaneously building local trust. That's what led the Chinese government to eventually legalize door-to-door sales for Western companies. The lessons from Amway's success in China speak directly to how a business can meet its anti-bribery Foreign Corrupt Trade Practices requirements and other compliance goals when doing business in a foreign country. Respect the local culture, be a responsible corporate citizen, and don't lose sight of the long-term opportunities."Media Contact: Mary Flood,

Investments in Energy Matthew SteppSenior Policy AnalystInformation Technology and Innovation Foundation"Much more innovation is necessary to achieve deep and affordable carbon reductions. Yet almost all of the policy and funding today focuses on deploying current technologies. U.S. investment in energy innovation is less than 5 percent of federal spending on defense research and demonstration. That has to change. We need better, cheaper options if the grid is to produce less carbon."In an Op Ed in the Washington Post Matthew Stepp argues current renewable energy technologies are not sufficient to address the challenge of climate change: Stepp is also the author of "Breaking Down Federal Investments in Clean Energy" ( and "The Future of Global Climate Policy" ( He is based in Washington, D.C.ProfNet Profile: Website: http://itif.orgMedia Contact: William Dube,

Responsive Web Design: Future of Internet Hassan BawabCEO and founderMagic Logix"Responsive Web design is the future of the Internet. More mobility requires the flexibility for websites to be viewed in a variety of ways, on a variety of devices. Businesses that capitalize on this lasting trend are at a competitive advantage in the marketplace."Bawab, known as "The Magi of the Internet," has 12 years of experience building websites for mid-size to Fortune 500 companies. He is a noted speaker at conferences including SMX East, Dallas Drupal Days, and the University of North Texas. He can speak on a variety of Web design, social media and SEO topics, and is most passionate about responsive Web design, why companies should use it and the best practices for creating RWD sites. He is based in Dallas and fluent in Arabic.ProfNet Profile: http://www.magiclogix.comMedia Contact: Laura Madison,


1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.19 0.00%
FB $118.06 0.00%
GOOG $695.70 0.00%
TSLA $222.56 0.00%
YHOO $37.40 3.90%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs